News

Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce the signature of a manufacturing services agreement with Exelixis, a commercially successful, oncology-focused US biotechnology company, for the cGMP clinical production of...

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553,...

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics,  announced multiple advancements in its 4-1BB bispecific antibody portfolio. Stimulation of 4-1BB is a promising therapeutic strategy for improving the current immunotherapy for cancers....

Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that it has signed an exclusive worldwide licensing agreement with Altesa Biosciences, Inc. to allow Altesa to develop and...

Medisafe, a leading digital drug companion company, announced the findings from two validation studies examining the impact of its digital drug companion on persistence to specialty medications (Rx). Led by Komodo Health, the analysis used real-world patient data to...

The University of Oxford has launched a Phase I trial of a novel mosaic vaccine targeting a ‘broad range’ of HIV variants. The HIV-CORE 0052 trial, part of the European Aids Vaccine Initiative, will involve 13 healthy HIV-negative adults aged...